Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of FGLL in patients with Alzheimer's disease.

Trial Profile

Phase II trial of FGLL in patients with Alzheimer's disease.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2011

At a glance

  • Drugs FGLL (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors ENKAM Pharmaceuticals A/S
  • Most Recent Events

    • 13 Dec 2011 Status changed from planning to discontinued.
    • 22 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top